Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing precision medicines for genetically defined diseases. Its lead program is bezuclastinib, which the company is advancing for systemic mastocytosis (SM) and gastrointestinal stromal tumor (GIST), alongside earlier-stage kinase inhibitor programs.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaA precision-medicine kinase inhibitor being developed for SM and GIST, with potential U.S. and select international commercialization.
Earlier-stage targeted oncology and rare-disease programs including CGT4859, CGT4255, and CGT6297.
Internal discovery efforts in JAK2, KRAS, and other undisclosed programs intended to expand the pipeline.
Asiakkaat
Cogent does not currently sell approved products, so its near-term 'customers' are primarily patients, physicians, and treatment centers participating in clinical trials. If bezuclastinib is approved, the commercial customer base would be hematologists, oncologists, specialty pharmacies, hospitals, and payors in rare-disease and oncology markets.
Patients with SM, GIST, and other genetically driven diseases enrolled in trials, and the physicians/sites running those studies.
Specialists who would prescribe bezuclastinib after approval because the target diseases are managed in specialty care settings.
Distribution and dispensing channels for a future commercial launch, especially for rare-disease and oncology drugs.
Potential collaborators that can provide local market access, sales, and distribution capabilities outside the U.S.
Strategia
Cogent's strategy is centered on advancing bezuclastinib through regulatory approval and, if approved, launching it in SM and GIST. The company is also trying to broaden value through pipeline expansion, selective partnerships, and licensing arrangements that can add development capability or geographic reach.
This is the lead asset and the main path to first product revenue and value creation.
A broader pipeline reduces single-asset dependence and supports longer-term growth.
External partners can provide local market access, development support, and commercialization scale.
Maantiede
Cogent is headquartered in the United States and currently conducts most of its business there through R&D, clinical development, and corporate operations. Management has said bezuclastinib could be commercialized in the U.S. and select international markets, with partnerships considered where local expertise or scale is needed.
Riskit
Cogent is highly dependent on bezuclastinib, so clinical, regulatory, or commercial setbacks in that program would have an outsized impact. As a pre-revenue biotech, it also faces financing risk, manufacturing and supply-chain dependence, and competition from better-funded companies with similar precision-medicine strategies.
- Bezuclastinib development riskVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company says its business is highly dependent on the success of bezuclastinib and related trials.
Kohdistuu: Lead asset for SM and GIST
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
Cogent has no product revenue and expects to fund operations through equity, debt, and collaborations.
Kohdistuu: Pre-commercial stage cash burn
- Manufacturing and supply-chain concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
API and drug product for bezuclastinib are sourced from single-source suppliers.
Kohdistuu: Clinical supply and future commercial launch
- Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Approval depends on successful clinical data and FDA/EMA review outcomes.
Kohdistuu - Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Larger pharma and biotech companies may develop safer, more effective, or faster-approved therapies.
Kohdistuu: Precision medicine and rare-disease oncology
Kirjanpito
Harkinnanvaraiset erätClinical trial and manufacturing costs are estimated before invoices are finalized, affecting quarterly expense timing.
Vaikutus: Can shift reported R&D expense and net loss between periods
The company uses Monte Carlo and probability judgments for awards with market or performance conditions.
Vaikutus: Affects operating expense and equity compensation trends
The company expects to finance operations through external capital until product revenue begins.
Vaikutus: Dilution, debt covenants, and financing costs may affect future statements
Most development spending is expensed as incurred, so trial progress directly affects earnings.
Vaikutus: R&D intensity remains the main driver of losses
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Nuvalent, Inc.
Pharmaceutical Preparations
Pliant Therapeutics, Inc
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
Solid Biosciences Inc.
SLDB · Biological Products, (No Diagnostic Substances)
Sagimet Biosciences Inc.
SGMT · Pharmaceutical Preparations
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Päivitetty: 24.9.2026